An investigation on behalf of investors in PTC Therapeutics, Inc. (NASDAQ:PTCT) shares over potential wrongdoing at PTC Therapeutics, Inc. was announced.
San Diego, CA -- (SBWIRE) -- 01/25/2018 -- An investigation was announced for investors in NASDAQ:PTCT shares concerning potential breaches of fiduciary duties by certain directors at PTC Therapeutics.
Investors in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain PTC Therapeutics directors breached their fiduciary duties and caused damage to the company and its shareholders.
On February 23, 2016, PTC Therapeutics, Inc. announced that it received a Refuse to File letter from the United States Food and Drug Administration ("FDA") regarding PTC Therapeutics' New Drug Application ("NDA") for Translarna™ (ataluren), an oral, first-in-class, protein restoration therapy for the treatment of nonsense mutation Duchenne muscular dystrophy ("nmDMD").
On March 3, 2016, a lawsuit was filed against PTC Therapeutics, Inc. (NASDAQ:PTCT) over alleged securities laws violations. The plaintiff claims that between May 6, 2014 and February 23, 2016, the defendants made allegedly false and/or misleading statements and/or failed to disclose that the Company's NDA for Translarna that it submitted to the FDA was not sufficiently complete to permit a substantive review of the application, that, as such, the application would not be reviewed nor approved by the FDA, that the impending non-approval of the NDA would have a negative material impact on the Company's operations and prospects, and that, as a result of the foregoing Defendants' statements about PTC Therapeutics' business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
Those who purchased shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels